Introduction
Two pharmacologically distinct binding site subtypes, central and peripheral, have been demonstrated for the benzodiazepines.
The central benzodiazepine receptor is localized on neuronal tissue and is the site at which benzodiazepine ligands are thought to exert their anxiolytic, anticonvulsant and muscle relaxant effects (Tallman and Gallager, 1985; Tallman et al., 1982; Haefely, 1983) . The peripheral benzodiazepine binding site (PBS), so named for its initial identification in peripheral tissues including adrenal cortex, kidney and heart (DeSouza et al., 1985; Davies and Huston, 1981) , is present mainly outside the CNS but is also present in olfactory bulb of rat and in low concentrations in brain glial cells (Anholt et al., 1984; Schoemaker et al., 1982) . These two binding site subtypes can be pharmacologically distinguished through the use of highly selective ligands. Thus clonazepam, a potent anticonvulsant, binds to the central receptor *All correspondence should be addressed to: Dr Donald M.
Wieland, Division of Nuclear Medicine, 3057 Phoenix Memorial Laboratory, The University of Michigan, 2301 Bonisteel Blvd, Ann Arbor, MI 48109-2100, U.S.A. TCurrent address: Egritech, Portland, ME 04101, U.S.A. with nanomolar affinity but to the PBS with less than micromolar affinity (Wang et al., 1984) . Conversely, both Ro 5-4864 [7-chloro-1,3-dihydro-1-methyl-5-(4'-chlorophenyl)-2H-1 &benzodiazepine-2-one] and the non-benzodiazepine PK 11195 [l-(tchlorophenyl)-N-methyl-N-( 1 -methyl-propyl)-3-isoquinoline carboxamide], which exhibit no anxiolytic activity, bind to the PBS in rat tissues with nanomolar affinity but have at least a lOOO-fold lower affinity for the central receptor (Wang er al., 1984; Dubroeucq et al., 1982) . These binding site subtypes are further differentiated by the lack of effect of y-amino butyric acid on ligand binding to the PBS, in contrast to its effect on ligand binding to the central receptor (Schoemaker et al., 1982; Marangos et al., 1982) .
Recently, C6 gliomas grown intracranially in rats have been successfully delineated from normal brain by in uiuo autoradiographic studies using 3H-labeled PK 11195 (Starosta-Rubenstein et al., 1987) . High concentrations of the PBS have also been demonstrated in human glial tumors (Starosta-Rubenstein et al., 1987; Olson et al., 1988) . Furthermore, ["C]PK 11195 has been used to map heart PBS in uivo (Charbonneau et al., 1986) . These studies suggested that a radioiodine labeled analog of PK 11195 might have clinical utility for single photon emission computed tomography (SPECT) imaging of the PBS including those in human glioma. We report the synthesis of a high specific activity '*'I-labeled analog of PK 11195, its in vitro affinity for the PBS in human glioblastoma cells, and in vivo brain autoradiographic studies in C, glioma bearing rats which demonstrate selective binding of the ligand to the tumor.
Experimeotal

Materials and method
No-carrier-added sodium ['251 ]iodide in 0.1 N NaOH was obtained from DuPont/New England Nuclear, Boston, Mass. PK 11195 was a generous gift of Pharmuka Laboratories, Gennevilliers, France. All solvents were HPLC grade and all other reagents were the best available quality. Silica Sep-Paks were obtained from Waters Associates (Milford, Mass.) Two HPLC systems were used. System 1 consisted of a Waters Associates Model 590 programmable solvent delivery module and a Model U6K injection valve. The stationary phase consisted of two pPorasil@ columns in series [( 150 + 300) mm x 3.9 mm, lo-pm particle, silica; Waters Associates], and the column was eluted with THF/hexane (15 : 85) at a flow rate of 2.5 mL/min. Radioactivity in the effluent was monitored with a Model RM-14 geiger counter (Eberline Instrument Co., Santa Fe, N.M.), and radioactivity in the collected fractions was measured in a Model CRC-12 Radioisotope Calibrator (Capintec Inc., Ramsey, N.J.). System 2 consisted of a Waters Associates Model 680 gradient controller, two Model 510 pumps and Model U6K injector and a reversed-phase pBondapak@ column (3.9 = 300 mm, lo-pm particle, C-18; Waters Associates). Column effiuent was monitored for both radioactivity (Flo-One@ Model DR/ IC radioactivity detector fitted with a 13OpL solid scintillator cell, Radiomatic Instruments, Tampa, Fla.) and U.V. absorbance (Model SF773 UV/VIS detector, Kratos, Ramsey, N.J.). Radio-TLC analyses were performed on silica gel coated glass plates (2 x 20 cm, Whatman K6F); the radioactive product was in all cases spotted over unlabeled PK 11195. The plates were analyzed on a Berthold Model LB 2832 Automatic TLC-Linear Analyzer.
Synthesis of [12?]PK I I195 (1)
The reaction mixture, which consisted of ca 6mg of (NH&SO1, O.lmg of PK 11195 and cu 6mCi of ['251 ]NaI in 15-30 PL of 0.1 N NaOH, dissolved in 0.3 ml of EtOH/H,O (1:2), was added to a 5 mL multi-dose vial containing 3 mm glass beads (Fig. 1) . The solvent was evaporated by heating the reaction vessel to 230°C. Air (10 mL) was then slowly injected and heating was continued at 230°C for an additional 20 min. The reaction vessel was cooled to room temperature, and the mixture was extracted with ethanol and analyzed by radio-TLC using either EtOAc or hexane: EtOAc (1: 2) as eluant. After evaporating the ethanol under an argon stream, the mixture was extracted with hexane and transferred to a silica Sep-Pak to remove free iodide. PK 11195 and 1 were co-eluted with EtOAc. This fraction was then concentrated under an argon stream in preparation for separation by normal-phase HPLC. An aliquot of this product was removed and analyzed for chemical purity, radiochemical purity, and effective specific activity by radio-HPLC, using HPLC System 2 with solvent system consisting of CH,CN:H,O (55:45), a flow rate of 2.0 mL/min, and detection at 223 nm. The retention times for PK 11195 and 1 were 8.6 and 9.6 min, respectively, in this system. For the quantitation of the effective specific activity, the concentration of residual, unlabeled PK 11195 was determined by comparing its peak height with that of authentic standard of known concentration, while the amount of radioactive 1 was determined by counting an aliquot of the preparation in an autogamma counter. The product was obtained in 50-76% radiochemical yield, ~94% radiochemical purity, and an effective specific activity of 15-l 7 Ci/mmol.
Purajkation of 1 by HPLC
HPLC system 1 was used to separate 1 from unlabeled PK 11195. In this system, the retention times for PK 11195 and 1 were 15.0 and 18.5, respectively. During elution of the radioactive peak, I-min fractions were collected. The radioactivity in each fraction was then assayed and the heart fractions were pooled. An aliquot of this product was removed and analyzed for chemical purity, radiochemical purity, and effective specific activity as described above. After preparative HPLC, the effective specific activity increased to 260-910 Ci/mmol. In other words, each mCi of no-carrieradded 1 contained 0.38-1.36pg of unlabelled PK 11195. The radiochemical purity was >99%. The radiochemical yield following HPLC purification was lo-20%.
Synthesis of ortho -['251]Iodobenzylguanidine (2)
The reaction mixture, which consisted of ca 4 mg of @JH&304, 0.1 mg of o-chlorobenzylguanidine and ca 2mCi of [L251]NaI, in 15-3OpL of 0.1 N NaOH, dissolved in 0.3 mL of H,O, was added to a 5 mL multi-dose vial containing 3 mm glass beads (Fig. 2) . The solvent was evaporated by heating the reaction vessel to a temperature of 190°C. Air (10 mL) was then slowly injected, and heating was continued for an additional 30 min. After cooling the reaction vessel to room temperature, the mixture 'was extracted with H,O and analyzed by radio-TLC, using EtOH : EtOAc (1: 1) as eluant. The mixture was then transferred to a Cellex D column (acetate form, 0.5 x 2.5 cm; BioRad, Richmond, Calif.) to remove free iodide. The o-chlorobenzylguanidine and 2 were co-eluted with 0.005 M sodium acetate buffer, pH 4.5. To determine the regioselectivity of the reaction, the reaction mixture was subjected to radio-HPLC analysis using System 2 with a solvent system consisting of 0.1 M NH,H,PO,/THF (88: 12), a flow rate of 2.0 mL/min, and detection at 254 nm. In this system, the retention times for m-, o-, and p-iodobenxylguanidine, which had been synthesized as previously described , were 5.1, 7.9 and 9.5 min respectively. The reaction provided 2 in ~95% radiochemical yield and > 98% radiochemical and chemical purity. Radio-HPLC analysis of 2 spiked with unlabeled m -, o -and p -iodobenzylguanidine demonstrated only one radioactive peak which co-eluted with authentic o -iodobenzylguanidine.
Binding to cultured human glioma cells
Human glioblastoma line U2r1 was obtained from Dr Darrel Bigner of Duke University. Monolayers of tumor cells were grown in 24 well plates. Media of exponentially growing cells was replaced with phosphate buffered saline, pH 7.4, for 10 min at 4°C. This prewash buffer was aspirated and replaced with buffer containing 1 (1 pM-25 nM). Nonspecific binding was determined in the presence of 10 pM unlabeled PK 11195. Following a 15 min incubation at 4°C the ligand mixture was removed by aspiration. The labeled monolayers were washed 3 x 7.5 min with buffer at 4°C. Cells were removed from the wells with trypsin and placed into vials for the measurement of radioactivity by liquid scintillation counting.
In vivo autoradiography
Two to three weeks before the study, male Wistar rats (200-300 g) were imroculated intracerebrally with a suspension of C, glioma cells as previously described 1988) . On the day of the study, the rats were catheterized as previously described (Ciliax et al., 1986) and pretreated iv. with either 5mg/kg of PK 11195 dissolved in dimethyl sulfoxide : ethanol (1: 1) or vehicle (0.1 mL/kg) 30 min before receiving a bolus injection of 400 pCi of 1 into the contralateral femoral vein. Twenty minutes after administration of 1, the animals were sacrificed by i.v. injection of 1 mL of saturated aqueous KCI. The brains, containing gliomas, were rapidly removed and frozen on dry ice. Thin ultracryotomy sections (20 pm) through the tumor were thaw mounted onto gelatin coated glass slides and apposed to SB-5 x-ray film (Eastman Kodak Co., Rochester, N.Y.). After 3-7 days exposure, the film was developed in GBX developer to produce autoradiograms.
To visualize tumor cell bodies, adjacent sections were stained for Nissl substance by cresyl violet. information on the effect of substitution with bromine or iodine. If iodine could be introduced into PK 11195 without either dramatically reducing the compound's affinity or altering its selectivity for the PBS, then one might be able to develop an agent for SPECT imaging and possibly radiotherapy. Since unlabeled 1 was not available, an '2sI-for-1271 exchange was not possible. However, the presence of chlorine in the 2'-position of PK 11195 offered the opportunity to radiolabel PK 11195 with "'1 by a solid-state interhalogen exchange method. The synthesis of 1, shown in Fig. 1 , was achieved by the solid-state exchange technique which we have previously described , but modified as to temperature, reaction time and the inclusion of 3 mm glass beads to lower iodine volatility. Temperatures from 160 to 230°C were tested, but only at 230°C was 1 produced. At 23o"C, the reaction time was varied from 20 to 60 min. The reaction was found to be complete at 20min, and an increase in reaction time resulted only in a reduced yield. The synthesis of 2 from o-chlorobenzylguanidine by this method (Fig. 2) was optimal at 190°C. This lower energy requirement for the interhalogen exchange of o -chlorobenzylguanidine than for PK 11195 may reflect greater steric accessibility of chlorine in the benzylguanidine. A previous attempt to synthesize 2 from o-chlorobenzylguanidine without glass beads gave poor radiochemical yields. However, subsequent inclusion of 3 mm glass beads to lower iodine volatility has dramatically increased the radiochemical yield of 2 to > 95% in 30 min. Synthesis of 1 without glass beads was not attempted.
Results and Discussion
When applied to PK 11195, this modified exchange technique yielded 1 in 50-76% radiochemical yield, >94% radiochemical purity and effective specific activity of 15-17 Ci/mmol. Subsequent normal-phase, preparative radio-HPLC purification provided 1 in ~99% radiochemical purity. The effective specific activity was 260-910 Ci/mmol; each mCi of 1 contained 0.38-1.36 pg of unlabelled PK 11195. Because of sacrificial losses incurred in collecting heart fractions, which was necessitated by the anomalous elution order in which the more lipophilic 1 eluted after PK 11195 on normal-phase HPLC, the overall radiochemical yield was reduced to lo-20%. Several other normal-phase HPLC systems were tested but did not reverse the elution order. We believe that this anomalous chromatographic behavior of 1 on normal phase is due to an "ortho effect" in which the bulkier iodine atom displaces the I-phenyl ring from the plane of the isoquinoline ring thus exposing the isoquinoline nitrogen to increased binding to silica.
An attractive feature of this new radioiodide exchange technique is that it can provide a radioiodinated ligand of high effective specific activity, potentially no-carrier-added, even when an appropriate iodinated precursor is not available. The identity of 1 was initially based on three pieces of indirect evidence: (1) the similar chromatographic behavior of 1 PK 11195 on TLC and HPLC, (2) the lack of reactivity of deschloro-PK 11195 under identical radioiodinated conditions, and (3) the regioselectivity of the analogous synthesis of 2 from o-chlorobenzylguanidine. The last point was determined by reversedphase radio-HPLC by spiking 2 with authentic samples of m-, o-and p-iodobenzylguanidines and demonstrating the co-elution of 2 with o-iodobenzylguanidine. No radioiodinated m -or p -iodobenzylguanidine was produced. To confirm the identity of 1, unlabeled 1 was recently synthesized in our laboratory (Gildersleeve et al., manuscript in preparation) and found to co-elute with 1 on radio-HPLC.
Both RoS-4864 and the benzodiazepine flunitrazepam bind with high affinity to PBS in rat tissues and are capable of differentiating tumour from normal brain in rat models (Starosta-Rubinstein et al., 1987) . In contrast, these ligands bind with low affinity (< 1 PM) to human glioma cells and are incapable of distinguishing tumor from normal brain parenchyma in autoradiographic studies of post mortem human brain containing glioma (Olson et al., 1988) . The application of 1 to the in vivo imaging of brain tumors by autoradiography in Cs glioma bearing rats is illustrated in Fig. 3(B) . A previously reported for [)H]PK 11195 (Starosta-Rubenstein et al., 1987) , a dense accumulation of radioactivity was observed in the tumor. A high correspondence between PBS binding of 1 and the distribution of intact tumor cells could be seen when autoradiograms were compared with Nissl stains of adjacent sections [ Fig. 3(A) ]. Even small foci of infiltrating tumor cells were imaged by 1. The accumulation of radioactivity in tumor tissue was blocked by pretreatment of the animal with unlabeled PK 11195 (5 mg/kg, i.v.), which strongly suggests that the uptake of 1 reflects specific binding to tumor cell PBS.
This work demonstrates that a radioiodine-labeled analog of PK 11195 can be synthesized in high specific activity by an interhalogen exchange method. Furthermore, after the introduction of iodine at the 2'-position of PK 11195, the ligand is still recognized by the PBS. More detailed autoradiographic and pharmacologic studies of 1, as well as the synthesis of its '231-labeled analog, will be reported subsequently. Additionally, this solid-state interhalogen exchange method is being applied to the synthesis of other radioiodinated ligands, including the synthesis of 3-[1251]iodo-MK-801 from 3-bromo-MK-801, an analog Autoradiogram of adjacent section demonstrating the in oiuo labeling of C, glioma with 1. The animal received an i.v. bolus of400 PCi of 120 min before death. Little uptake of radioactivity is observed in normal brain; the concentration ratio of radioactivity for ghoma to noninvolved cortical tissue was 3: 1. Radioactivity concentration increases in the following order: black < violet < blue < green c yellow < orange < red < white.
42-l of the NMDA receptor antagonist MK-801 . These initial results in rat C, glioma indicate that ligand 1 is superior to radioiodinated benzodiazepine analogs of the PBS antagonist Ro5-4864 recently studies in our laboratory (Van Dort et al., 1988) . The tumor-to-cortex tissue concentration ratio obtained with 1 is higher than that observed with the Ro5-4864 analogs. Also, there is no evidence for the uptake of 1 by white matter as was the case with the radioiodinated benzodiazepines. These findings lend support to further study of '*%l or a related '231-labeled analog of PK 11195 as possible tools for the in uiuo localization and PBS characterization of glioma in humans by SPECT.
